Search Results - "Dahle, C"

Regional brain shrinkage over two years: Individual differences and effects of pro-inflammatory genetic polymorphisms by Persson, N., Ghisletta, P., Dahle, C.L., Bender, A.R., Yang, Y., Yuan, P., Daugherty, A.M., Raz, N.

“…We examined regional changes in brain volume in healthy adults (N=167, age 19–79years at baseline; N=90 at follow-up) over approximately two years. With latent…”
Get full text

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis by Håkansson, I., Tisell, A., Cassel, P., Blennow, K., Zetterberg, H., Lundberg, P., Dahle, C., Vrethem, M., Ernerudh, J.

“…Background and purpose Improved biomarkers are needed to facilitate clinical decision‐making and as surrogate endpoints in clinical trials in multiple…”
Get full text

Combined monthly GRACE-FO gravity fields for a Global Gravity-based Groundwater Product by Meyer, U, Lasser, M, Dahle, C, Förste, C, Behzadpour, S, Koch, I, Jäggi, A

“…SUMMARY The Combination Service for Time-variable Gravity fields (COST-G) operationally provides combinations of monthly Earth gravity field models derived…”
Get full text

Longitudinal anti‐nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent‐onset disease by Frodlund, M., Wetterö, J., Dahle, C., Dahlström, Ö., Skogh, T., Rönnelid, J., Sjöwall, C.

“…Summary Serum immunoglobulin (Ig)G anti‐nuclear antibodies (ANA) detected by indirect immunofluorescence (IF) microscopy remains a hallmark of systemic lupus…”
Get full text

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid by Mellergård, J., Edström, M., Vrethem, M., Ernerudh, J., Dahle, C.

“…Natalizumab exerts impressive therapeutic effects in patients with multiple sclerosis (MS). The proposed main mode of action is reducing transmigration of…”
Get full text

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes by Ahmad, A., Heijke, R., Eriksson, P., Wirestam, L., Kechagias, S., Dahle, C., Sjöwall, C.

“…In this study, IgG‐autoantibodies associated with autoimmune hepatitis and primary biliary cholangitis (PBC) were found in a considerable proportion of…”
Get full text

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5) by Forsberg, L., Ekström, E., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Lantblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Introduction : Dimethyl fumarate (DMF) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS). DMF is included in the Swedish post-market…”
Get full text

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1) by Forsberg, L., Ekström, E., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Introduction : Natalizumab (NTZ) is a highly effective disease modulatory treatment for relapsing-remitting multiple sclerosis (RRMS). Post-marketing…”
Get full text

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10) by Rosengren, V., Forsberg, L., Ekström, E., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Introduction : Cladribine is a deoxyadenosine analogue prodrug that selectively induces immune reconstitution by targeting B- and T-lymphocytes. Cladribine…”
Get full text

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab‐treated multiple sclerosis by Mellergård, J., Tisell, A., Blystad, I., Grönqvist, A., Blennow, K., Olsson, B., Dahle, C., Vrethem, M., Lundberg, P., Ernerudh, J.

“…Background and purpose Brain atrophy is related to clinical deterioration in multiple sclerosis (MS) but its association with intrathecal markers of…”
Get full text

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) by Ekström, E., Rosengren, V., Kågström, S., Forsberg, L., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Alemtuzumab (ALZ) is a modulatory drug for patients with relapsing-remitting multiple sclerosis (RRMS). Post-marketing surveillance is important…”
Get full text

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10) by Rosengren, V., Ekström, E., Forsberg, L., Kågström, S., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Cladribine is a deoxyadenosine analogue prodrug that selectively induces immune reconstitution by targeting B- and T-lymphocytes. Cladribine…”
Get full text

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4) by Rosengren, V., Ekström, E., Forsberg, L., Kågström, S., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Teriflunomide (TFM) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS) included in the Swedish post-market surveillance study…”
Get full text

Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile by Ekström, E., Rosengren, V., Kågström, S., Forsberg, L., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Subcutaneous peginterferon beta-1a (PegIFN) was approved for relapsing-remitting multiple sclerosis (RRMS) in Europe 2014. Phase II and III…”
Get full text

The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study by Ekström, E., Rosengren, V., Kågström, S., Forsberg, L., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Natalizumab (NTZ) is a highly effective disease modulatory treatment for relapsing-remitting multiple sclerosis (RRMS). Post-marketing…”
Get full text

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5) by Rosengren, V., Ekström, E., Forsberg, L., Kågström, S., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Dimethyl fumarate (DMF) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS). DMF is included in the Swedish post-market…”
Get full text

Simulating high-frequency atmosphere-ocean mass variability for dealiasing of satellite gravity observations: AOD1B RL05 by Dobslaw, H., Flechtner, F., Bergmann-Wolf, I., Dahle, C., Dill, R., Esselborn, S., Sasgen, I., Thomas, M.

“…An improved version of the OMCT ocean model with 1° spatial resolution provides bottom pressure anomalies for the new release 05 of the GRACE Atmosphere and…”
Get full text

Efficacy and safety in patients treated with natalizumab for at least 10 years - real-world data from a swedish national surveillance study (IMSE 1) by Kågström, S., Leandersson, Å., Forsberg, L., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Sundström, P., Martin, C., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Natalizumab (NTZ) is a highly effective disease modulatory treatment for relapsing-remitting multiple sclerosis (RRMS). Post-marketing…”
Get full text

A swedish post-market surveillance study: long-term effectiveness and safety of dimethyl fumarate (imse 5) for patients treated at least 36 months: on-demand eposters p0001-p0286 by Forsberg, L., Kågström, S., Leandersson, Å., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Dimethyl fumarate (DMF) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS). DMF is included in the Swedish post-market…”
Get full text

Relation of edss to patient-reported outcome measurements in ms: real-world data from a swedish nationwide study of fingolimod (imse 2) by Leandersson, Å., Kågström, S., Forsberg, L., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A. -M, Burman, J., Martin, C., Sundström, P., Gunnarsson, Martin, Piehl, F., Olsson, T.

“…Background : Fingolimod (FGL) is an oral disease-modifying therapy (DMT) for patients with relapsing-remitting multiple sclerosis, introduced in Sweden 2011…”
Get full text